RPRX - Royalty Pharma PLC Stock Price, Fair Value and News

28.80USD+0.12 (+0.42%)Market Closed

Market Summary

USD28.80+0.12

Market Closed

0.42%

RPRX Stock Price

View Fullscreen

RPRX RSI Chart

RPRX Valuation

Market Cap

12.9B

Price/Earnings (Trailing)

16.17

Price/Sales (Trailing)

5.77

EV/EBITDA

13.29

Price/Free Cashflow

4.93

RPRX Price/Sales (Trailing)

RPRX Profitability

EBT Margin

53.01%

Return on Equity

8.1%

Return on Assets

4.95%

Free Cashflow Yield

20.27%

RPRX Fundamentals

RPRX Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

-16.96%

Rev. Growth (Qtr)

-4.71%

RPRX Earnings

Earnings (TTM)

798.9M

Earnings Growth (Yr)

-98.6%

Earnings Growth (Qtr)

-99.03%

Breaking Down RPRX Revenue

Last 7 days

2.4%

Last 30 days

8.4%

Last 90 days

2.9%

Trailing 12 Months

-7.1%

How does RPRX drawdown profile look like?

RPRX Financial Health

Current Ratio

12.52

Debt/Equity

0.62

Debt/Cashflow

0.43

RPRX Investor Care

Dividend Yield

2.81%

Dividend/Share (TTM)

0.81

Shares Dilution (1Y)

0.68%

Diluted EPS (TTM)

1.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.2B	0	0	0
2023	2.4B	2.4B	2.3B	2.4B
2022	2.3B	2.3B	2.2B	2.2B
2021	2.4B	2.4B	2.5B	2.3B
2020	1.2B	1.6B	1.6B	1.9B
2019	1.2B	1.4B	1.6B	1.8B
2018	0	0	0	983.2M
2017	0	0	0	877.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Royalty Pharma PLC

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

CEO	Mr. Pablo Gerardo Legorreta
WEBSITE	royaltypharma.com
INDUSTRY	Biotechnology

Royalty Pharma PLC Frequently Asked Questions

What is the ticker symbol for Royalty Pharma PLC? What does RPRX stand for in stocks?

RPRX is the stock ticker symbol of Royalty Pharma PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Royalty Pharma PLC (RPRX)?

As of Fri Jul 26 2024, market cap of Royalty Pharma PLC is 12.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers.

Is Royalty Pharma PLC a good stock to buy?

The fair value guage provides a quick view whether RPRX is over valued or under valued. Whether Royalty Pharma PLC is cheap or expensive depends on the assumptions which impact Royalty Pharma PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPRX.

What is Royalty Pharma PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, RPRX's PE ratio (Price to Earnings) is 16.17 and Price to Sales (PS) ratio is 5.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPRX PE ratio will change depending on the future growth rate expectations of investors.